Haemonetics (HAE) Revenue (2009 - 2026)

Haemonetics' Revenue history runs 18 years deep, the most recent figure standing at $346.4 million for Q1 2026.

• In Q1 2026, Revenue rose 4.76% year-over-year to $346.4 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 1.97% YoY), while the FY2026 annual figure was $1.3 billion, down 1.97% from the prior year.
• Revenue was $346.4 million for Q1 2026 at Haemonetics, up from $339.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $348.5 million in Q4 2024 to a low of $259.8 million in Q1 2022.
• Historically, Revenue has averaged $316.5 million across 5 years, with a median of $324.4 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Revenue rose 24.01% in 2022, then slipped 5.27% in 2025.
• A 5-year view of Revenue shows it stood at $305.3 million in 2022, then climbed by 10.14% to $336.2 million in 2023, then rose by 3.66% to $348.5 million in 2024, then fell by 2.75% to $339.0 million in 2025, then grew by 2.18% to $346.4 million in 2026.
• The last three Revenue figures came in at $346.4 million (Q1 2026), $339.0 million (Q4 2025), and $327.3 million (Q3 2025), per Business Quant data.